Agios Pharmaceuticals (AGIO) Change in Acquisitions & Divestments (2012 - 2026)

Agios Pharmaceuticals (AGIO) has 15 years of Change in Acquisitions & Divestments data on file, last reported at $218.0 million in Q2 2026.

• Quarterly Change in Acquisitions & Divestments fell 1.2% year-over-year to $218.0 million in Q2 2026, while the trailing twelve-month figure through Jun 2026 was $1.0 billion (up 26.45% YoY) and the FY2025 annual result came in at $1.0 billion, up 26.26% from the prior year.
• Change in Acquisitions & Divestments fell to $218.0 million in Q2 2026, from $290.3 million in the prior quarter.
• In the past five years, Change in Acquisitions & Divestments ranged from a high of $368.7 million in Q1 2024 to a low of $141.9 million in Q2 2024.
• A 5-year average of $232.3 million and a median of $219.3 million in 2025 frame the typical range for Change in Acquisitions & Divestments.
• Annual changes were most pronounced in 2022 — Change in Acquisitions & Divestments jumped 147.84% — and 2023, when it sank 55.06%.
• Tracing AGIO's Change in Acquisitions & Divestments over 5 years: stood at $198.9 million in 2022, then retreated by 6.38% to $186.2 million in 2023, then slipped by 19.36% to $150.1 million in 2024, then soared by 68.03% to $252.3 million in 2025, then retreated by 13.59% to $218.0 million in 2026.
• The last three Change in Acquisitions & Divestments figures came in at $218.0 million (Q2 2026), $290.3 million (Q1 2026), and $252.3 million (Q4 2025), per Business Quant data.